Top

Published in:

01-08-2021 | Cervical Cancer | Original Contribution

6-Shogaol from ginger shows anti-tumor effect in cervical carcinoma via PI3K/Akt/mTOR pathway

Authors: Xiao-Dong Pei, Zhi-Long He, Hong-Liang Yao, Jun-Song Xiao, Lan Li, Jian-Zhong Gu, Pei-Zhao Shi, Jin-Hua Wang, Li-He Jiang

Published in: European Journal of Nutrition | Issue 5/2021

Abstract

Purpose

6-Shogaol, an active phenolic compound from ginger (Zingiber officinale), can inhibit the growth of a variety of human cancer cells. Nevertheless, its underlying molecular mechanisms in cervical cancer remain unclear. In this study, we systematically examine the inhibitory effect of 6-shogaol on cervical cancer in vitro and in vivo.

Methods

Cell proliferation was assessed by CCK8 assay and colony formation assay in HeLa and SiHa cells. We analyzed cell cycle and apoptosis through flow cytometry. GFP-LC3 puncta and transmission electron microscopy were used to observe autophagic bodies. Wound-healing assay and transwell assay were used for evaluating the migration of cells. Western blot was applied to detect protein expression levels.

Results

6-Shogaol could suppress cell proliferation and migration, cause cell cycle arrest in the G2/M phase in HeLa and SiHa cells. Moreover, 6-shogaol triggered the apoptosis process through the mitochondrial pathway by downregulating the expression levels of p-PI3K, p-Akt and p-mTOR. Further research indicated that the induction of apoptosis by 6-shogaol was remarkably decreased after the treatment of ROS scavenger and PI3K agonist. Additionally, 6-shogaol increased the number of LC3-positive puncta and autophagic bodies per cell in both HeLa and SiHa cells. Pretreatment of cells with Bafilomycin A1, an autophagy inhibitor, accelerated 6-shogaol mediated cell apoptosis, suggesting that induction of autophagy by 6-shogaol is suppressive to apoptosis. Furthermore, in vivo data revealed that 6-shogaol significantly inhibited tumor growth and cell proliferation in tumor tissues.

Conclusion

These findings suggested that 6-shogaol could be developed as a functional food ingredient, which is potentially used as therapeutic agents for patients with cervical cancer.

Available only for authorised users

Chrysostomou AC, Stylianou DC, Constantinidou A, Kostrikis LG (2018) Cervical cancer screening programs in Europe: the transition towards HPV vaccination and population-based HPV testing. Viruses. https://doi.org/10.3390/v10120729CrossRefPubMedPubMedCentral

Li H, Wu X, Cheng X (2016) Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol 27(4):e43. https://doi.org/10.3802/jgo.2016.27.e43CrossRefPubMedPubMedCentral

Mrklas KJ, MacDonald S, Shea-Budgell MA, Bedingfield N, Ganshorn H, Glaze S, Bill L, Healy B, Healy C, Guichon J, Colquhoun A, Bell C, Richardson R, Henderson R, Kellner J, Barnabe C, Bednarczyk RA, Letendre A, Nelson GS (2018) Barriers, supports, and effective interventions for uptake of human papillomavirus- and other vaccines within global and Canadian Indigenous peoples: a systematic review protocol. Syst Rev 7(1):40. https://doi.org/10.1186/s13643-018-0692-yCrossRefPubMedPubMedCentral

Ali BH, Blunden G, Tanira MO, Nemmar A (2008) Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale Roscoe): a review of recent research. Food Chem Toxicol 46(2):409–420. https://doi.org/10.1016/j.fct.2007.09.085CrossRefPubMed

Lantz RC, Chen GJ, Sarihan M, Solyom AM, Jolad SD, Timmermann BN (2007) The effect of extracts from ginger rhizome on inflammatory mediator production. Phytomedicine 14(2–3):123–128. https://doi.org/10.1016/j.phymed.2006.03.003CrossRefPubMed

Shukla Y, Singh M (2007) Cancer preventive properties of ginger: a brief review. Food Chem Toxicol 45(5):683–690. https://doi.org/10.1016/j.fct.2006.11.002CrossRefPubMed

Ling H, Yang H, Tan SH, Chui WK, Chew EH (2010) 6-Shogaol, an active constituent of ginger, inhibits breast cancer cell invasion by reducing matrix metalloproteinase-9 expression via blockade of nuclear factor-kappaB activation. Br J Pharmacol 161(8):1763–1777. https://doi.org/10.1111/j.1476-5381.2010.00991.xCrossRefPubMedPubMedCentral

Jolad SD, Lantz RC, Solyom AM, Chen GJ, Bates RB, Timmermann BN (2004) Fresh organically grown ginger (Zingiber officinale): composition and effects on LPS-induced PGE2 production. Phytochemistry 65(13):1937–1954. https://doi.org/10.1016/j.phytochem.2004.06.008CrossRefPubMed

Jolad SD, Lantz RC, Chen GJ, Bates RB, Timmermann BN (2005) Commercially processed dry ginger (Zingiber officinale): composition and effects on LPS-stimulated PGE2 production. Phytochemistry 66(13):1614–1635. https://doi.org/10.1016/j.phytochem.2005.05.007CrossRefPubMed

10.

Hung JY, Hsu YL, Li CT, Ko YC, Ni WC, Huang MS, Kuo PL (2009) 6-Shogaol, an active constituent of dietary ginger, induces autophagy by inhibiting the AKT/mTOR pathway in human non-small cell lung cancer A549 cells. J Agric Food Chem 57(20):9809–9816. https://doi.org/10.1021/jf902315eCrossRefPubMed

11.

Tan BS, Kang O, Mai CW, Tiong KH, Khoo AS, Pichika MR, Bradshaw TD, Leong CO (2013) 6-Shogaol inhibits breast and colon cancer cell proliferation through activation of peroxisomal proliferator activated receptor gamma (PPARgamma). Cancer Lett 336(1):127–139. https://doi.org/10.1016/j.canlet.2013.04.014CrossRefPubMed

12.

Liang T, He Y, Chang YH, Liu XT (2019) 6-shogaol a active component from ginger inhibits cell proliferation and induces apoptosis through inhibition of STAT-3 translocation in ovarian cancer cell lines (A2780). Biotechnol Bioproc E 24(3):560–567. https://doi.org/10.1007/s12257-018-0502-3CrossRef

13.

Li TY, Chiang BH (2017) 6-shogaol induces autophagic cell death then triggered apoptosis in colorectal adenocarcinoma HT-29 cells. Biomed Pharmacother 93:208–217. https://doi.org/10.1016/j.biopha.2017.06.038CrossRefPubMed

14.

Kondo Y, Kanzawa T, Sawaya R, Kondo S (2005) The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5(9):726–734. https://doi.org/10.1038/nrc1692CrossRefPubMed

15.

Levine B, Klionsky DJ (2004) Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 6(4):463–477. https://doi.org/10.1016/s1534-5807(04)00099-1CrossRefPubMed

16.

Codogno P, Mehrpour M, Proikas-Cezanne T (2011) Canonical and non-canonical autophagy: variations on a common theme of self-eating? Nat Rev Mol Cell Biol 13(1):7–12. https://doi.org/10.1038/nrm3249CrossRefPubMed

17.

Carew JS, Nawrocki ST, Kahue CN, Zhang H, Yang C, Chung L, Houghton JA, Huang P, Giles FJ, Cleveland JL (2007) Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 110(1):313–322. https://doi.org/10.1182/blood-2006-10-050260CrossRefPubMedPubMedCentral

18.

Man S, Wang H, Zhou J, Lu Y, Su Y, Ma L (2019) Cardiac glycoside compound isolated from Helleborus thibetanus Franch displays potent toxicity against HeLa cervical carcinoma cells through ROS-independent autophagy. Chem Res Toxicol 32(12):2479–2487. https://doi.org/10.1021/acs.chemrestox.9b00318CrossRefPubMed

19.

Wang Q, Yan SP, Chu DX, Xie Y, Wang CF, Zhang JY, Li WC, Guo RX (2019) Silencing of Long Non-Coding RNA RP1-93H18.6 acts as a tumor suppressor in cervical cancer through the blockade of the PI3K/Akt axis. Mol Ther Nucleic Acids 19:304–317. https://doi.org/10.1016/j.omtn.2019.10.041CrossRefPubMedPubMedCentral

20.

Weidner MS, Sigwart K (2000) The safety of a ginger extract in the rat. J Ethnopharmacol 73(3):513–520. https://doi.org/10.1016/s0378-8741(00)00340-8CrossRefPubMed

21.

Mahomoodally MF, Aumeeruddy MZ, Rengasamy KRR, Roshan S, Hammad S, Pandohee J, Hu X, Zengin G (2019) Ginger and its active compounds in cancer therapy: from folk uses to nano-therapeutic applications. Semin Cancer Biol. https://doi.org/10.1016/j.semcancer.2019.08.009CrossRefPubMed

22.

Schwartz GK, Shah MA (2005) Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 23(36):9408–9421. https://doi.org/10.1200/JCO.2005.01.5594CrossRefPubMed

23.

Wu JJ, Omar HA, Lee YR, Teng YN, Chen PS, Chen YC, Huang HS, Lee KH, Hung JH (2015) 6-Shogaol induces cell cycle arrest and apoptosis in human hepatoma cells through pleiotropic mechanisms. Eur J Pharmacol 762:449–458. https://doi.org/10.1016/j.ejphar.2015.06.032CrossRefPubMed

24.

Ray A, Vasudevan S, Sengupta S (2015) 6-Shogaol inhibits breast cancer cells and stem cell-like spheroids by modulation of notch signaling pathway and induction of autophagic cell death. PLoS One 10(9):e0137614. https://doi.org/10.1371/journal.pone.0137614CrossRefPubMedPubMedCentral

25.

Ishiguro K, Ando T, Watanabe O, Goto H (2008) Specific reaction of alpha, beta-unsaturated carbonyl compounds such as 6-shogaol with sulfhydryl groups in tubulin leading to microtubule damage. FEBS Lett 582(23–24):3531–3536. https://doi.org/10.1016/j.febslet.2008.09.027CrossRefPubMed

26.

Gan FF, Nagle AA, Ang X, Ho OH, Tan SH, Yang H, Chui WK, Chew EH (2011) Shogaols at proapoptotic concentrations induce G(2)/M arrest and aberrant mitotic cell death associated with tubulin aggregation. Apoptosis 16(8):856–867. https://doi.org/10.1007/s10495-011-0611-3CrossRefPubMed

27.

Park M, Chae HD, Yun J, Jung M, Kim YS, Kim SH, Han MH, Shin DY (2000) Constitutive activation of cyclin B1-associated cdc2 kinase overrides p53-mediated G2-M arrest. Cancer Res 60(3):542–545PubMed

28.

Xu C, Wang X, Zhu Y, Dong X, Liu C, Zhang H, Liu L, Huang S, Chen L (2016) Rapamycin ameliorates cadmium-induced activation of MAPK pathway and neuronal apoptosis by preventing mitochondrial ROS inactivation of PP2A. Neuropharmacology 105:270–284. https://doi.org/10.1016/j.neuropharm.2016.01.030CrossRefPubMedPubMedCentral

29.

Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9(1):47–59. https://doi.org/10.1038/nrm2308CrossRefPubMed

30.

Gong L, Tang Y, An R, Lin M, Chen L, Du J (2017) RTN1-C mediates cerebral ischemia/reperfusion injury via ER stress and mitochondria-associated apoptosis pathways. Cell Death Dis 8(10):e3080. https://doi.org/10.1038/cddis.2017.465CrossRefPubMedPubMedCentral

31.

Maiuri MC, Zalckvar E, Kimchi A, Kroemer G (2007) Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 8(9):741–752. https://doi.org/10.1038/nrm2239CrossRefPubMed

32.

Schumacker PT (2006) Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 10(3):175–176. https://doi.org/10.1016/j.ccr.2006.08.015CrossRefPubMed

33.

Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39(1):44–84. https://doi.org/10.1016/j.biocel.2006.07.001CrossRefPubMed

34.

White E (2012) Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 12(6):401–410. https://doi.org/10.1038/nrc3262CrossRefPubMedPubMedCentral

35.

Wang G, Zhang T, Sun W, Wang H, Yin F, Wang Z, Zuo D, Sun M, Zhou Z, Lin B, Xu J, Hua Y, Li H, Cai Z (2017) Arsenic sulfide induces apoptosis and autophagy through the activation of ROS/JNK and suppression of Akt/mTOR signaling pathways in osteosarcoma. Free Radic Biol Med 106:24–37. https://doi.org/10.1016/j.freeradbiomed.2017.02.015CrossRefPubMed

36.

Sui X, Chen R, Wang Z, Huang Z, Kong N, Zhang M, Han W, Lou F, Yang J, Zhang Q, Wang X, He C, Pan H (2013) Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis 4:e838. https://doi.org/10.1038/cddis.2013.350CrossRefPubMedPubMedCentral

37.

Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871–890. https://doi.org/10.1016/j.cell.2009.11.007CrossRefPubMed

38.

Savagner P (2015) Epithelial-mesenchymal transitions: from cell plasticity to concept elasticity. Curr Top Dev Biol 112:273–300. https://doi.org/10.1016/bs.ctdb.2014.11.021CrossRefPubMed

39.

Javadian M, Gharibi T, Shekari N, Abdollahpour-Alitappeh M, Mohammadi A, Hossieni A, Mohammadi H, Kazemi T (2019) The role of microRNAs regulating the expression of matrix metalloproteinases (MMPs) in breast cancer development, progression, and metastasis. J Cell Physiol 234(5):5399–5412. https://doi.org/10.1002/jcp.27445CrossRefPubMed

40.

Cheng G, Gao F, Sun X, Bi H, Zhu Y (2016) Paris saponin VII suppresses osteosarcoma cell migration and invasion by inhibiting MMP2/9 production via the p38 MAPK signaling pathway. Mol Med Rep 14(4):3199–3205. https://doi.org/10.3892/mmr.2016.5663CrossRefPubMedPubMedCentral

41.

Porta C, Paglino C, Mosca A (2014) Targeting PI3K/Akt/mTOR signaling in cancer. Front Oncol 4:64. https://doi.org/10.3389/fonc.2014.00064CrossRefPubMedPubMedCentral

42.

Ciruelos Gil EM (2014) Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat Rev 40(7):862–871. https://doi.org/10.1016/j.ctrv.2014.03.004CrossRefPubMed

Title: 6-Shogaol from ginger shows anti-tumor effect in cervical carcinoma via PI3K/Akt/mTOR pathway
Authors: Xiao-Dong Pei
Zhi-Long He
Hong-Liang Yao
Jun-Song Xiao
Lan Li
Jian-Zhong Gu
Pei-Zhao Shi
Jin-Hua Wang
Li-He Jiang
Publication date: 01-08-2021
Publisher: Springer Berlin Heidelberg
Keywords: Cervical Cancer
Cervical Cancer
Published in: European Journal of Nutrition / Issue 5/2021
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-020-02440-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2021

Ultra-processed food consumption patterns among older adults in the Netherlands and the role of the food environment

Daily vitamin D3 in overweight and obese children and adolescents: a randomized controlled trial

Ten days of complete fasting affected subjective sensations but not cognitive abilities in healthy adults

B vitamin blood concentrations and one-carbon metabolism polymorphisms in a sample of Italian women and men attending a unit of transfusion medicine: a cross-sectional study

A mendelian randomization study on causal effects of 25(OH)vitamin D levels on attention deficit/hyperactivity disorder

A bridge for short-chain fatty acids to affect inflammatory bowel disease, type 1 diabetes, and non-alcoholic fatty liver disease positively: by changing gut barrier

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials